NCT05672108RecruitingPhase 2
Phase II Trial of Lung Chemoemobolization
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then blocking off the blood supply to the tumors. Mitomycin (chemotherapy), Lipiodol (drug carrier), and Embospheres (small plastic beads that block off the artery) are injected into the tumor-feeding artery. This traps the chemotherapy inside the tumor and also cuts off the tumor\'s blood supply. As a result, the tumor is exposed to a high dose of chemotherapy, and is also deprived of nutrients and oxygen. TACE can be effective at controlling or stopping the growth of lung tumors.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 3 Jan 2023
- Start date
- 12 May 2023
- Primary completion date
- 28 Oct 2027
- Lead sponsor
- City of Hope Medical Center
- Diseases
- Lung cancer, Colorectal cancer, Sarcoma
- NCT number
- NCT05672108
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 12 May 2023 to the primary completion date, 28 Oct 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Planned radioactive iodine imaging or therapy (contraindication to lipiodol)
- Allergy to iodinated contrast that cannot be treated with steroid / diphenhydramine premedication
- Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, or that would affect subject safety
Other illness
- No measurable treatable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (for example, unable to measure tumor size on CT, or lung nodules are all \< 1 cm)
- Pulmonary hypertension (diagnosed or suspected on echocardiography, CT, magnetic resonance imaging \[MRI\], or direct pressure measurement)
- Active lung infection (pneumonia, empyema, or lung abscess requiring therapy within 1 month)
- Symptomatic heart failure (American College of Cardiology \[ACC\]/American Heart Association \[AHA\] stage C or D)
- Hyperthyroidism or history of hyperthyroidism, including subclinical hyperthyroidism (contraindication to lipiodol)
- Allergy to lipiodol or mitomycin
Lab values
- Renal failure (estimated glomerular filtration rate \[eGFR\] \< 30 mL/min/1.73 m\^2)
- Platelets \< 50,000 (after transfusion, if needed)
- International normalized ratio (INR) \> 2 (after transfusion, if needed)
- Hemoglobin \< 7 (after transfusion, if needed)
Other
- Eastern Cooperative Oncology Group (ECOG) performance status \> 2
- Oxygen saturation \< 92% on room air
- Forced expiratory volume in 1 second (FEV1) \< 60%
- Life expectancy \< 6 months
- Recent pulmonary embolism (within 3 months)
- Pulmonary arteriovenous malformation
- Left bundle branch block (contraindication to pulmonary angiography)
- Pregnancy or intent to become pregnant
- Breast feeding
- Altered mental status that would interfere with consent or follow-up
Who the study is looking for
- Lung cancer or lung metastases, with lung, endobronchial, pleural, or mediastinal tumors that are progressing on systemic therapy (or the patient cannot tolerate systemic therapy), and that are not amenable to resection, thermal ablation, or ablative radiation therapy
- Lung-dominant disease (majority of active tumor volume is in the chest)
- At least 18 years old
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| City of Hope Medical Center Coordinator of this site? Confirm its status | Duarte | United States | Recruiting |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.